Evidence map›Paper›PMID 25971971›Full record

ArticleThe Journal of biological chemistry2015

Regulation of ERK Kinase by MEK1 Kinase Inhibition in the Brain.

Tara C Tassin, David R Benavides, Florian Plattner, Akinori Nishi, James A Bibb

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Regulation of Phosphorylated State of NMDA Receptor by STEPAntioxidants (Basel, Switzerland) · 2021
    Article
  5. Review
  6. Frontiers in cellular neuroscience · 2020
    Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Tara C TassinFrom the Departments of Psychiatry and.
David R Benavidesthe Department of Neurology, The Johns Hopkins Hospital, Baltimore, Maryland 21287, and.
Florian PlattnerFrom the Departments of Psychiatry and.
Akinori Nishithe Department of Pharmacology, Kurume University School of Medicine, Kurume, Fukuoka 830-0011, Japan.
James A BibbFrom the Departments of Psychiatry and Neurology and Neurotherapeutics and Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, james.bibb@utsouthwestern.edu.
The University of Texas Southwestern Medical Center · USJohns Hopkins Hospital · USKurume University · JP

Funding

Basic Science Training Program in Drug Abuse ResearchT32DA007290 · NIDA · YALE UNIVERSITY · PI SELF, DAVID W · 1992 to 2017
$6.7M
The Role of Cdk5 in AddictionR01DA016672 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI BIBB, JAMES A · 2003 to 2010
$2.5M
Novel Signal Transduction Mechanisms in Learning and MemoryR01MH083711 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI BIBB, JAMES A · 2010 to 2014
$2.0M
The Role of Cdk5 in StrokeR01NS073855 · NINDS · UT SOUTHWESTERN MEDICAL CENTER · PI BIBB, JAMES A · 2012 to 2017
$1.7M
The Regulation of Dopamine Neurotransmission by CDK5R01MH079710 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI BIBB, JAMES A · 2008 to 2011
$1.7M
NMDA RECEPTOR REGULATION IN ADDICTIONR01DA033485 · NIDA · UT SOUTHWESTERN MEDICAL CENTER · PI BIBB, JAMES A · 2012 to 2016
$1.6M
NIDA NIH HHS DA016672NIDA NIH HHS DA033485NIDA NIH HHS R01 DA016672NIDA NIH HHS R01 DA033485NIDA NIH HHS T32 DA007290NIDA NIH HHS T32DA007290NIMH NIH HHS MH083711NIMH NIH HHS MH79710NIMH NIH HHS R01 MH079710NIMH NIH HHS R01 MH083711NINDS NIH HHS NS073855NINDS NIH HHS R01 NS073855
6 · The paper itself

Abstract

Metabotropic (slow) and ionotropic (fast) neurotransmission are integrated by intracellular signal transduction mechanisms involving protein phosphorylation/dephosphorylation to achieve experience-dependent alterations in brain circuitry. ERK is an important effector of both slow and fast forms of neurotransmission and has been implicated in normal brain function and CNS diseases. Here we characterize phosphorylation of the ERK-activating protein kinase MEK1 by Cdk5, ERK, and Cdk1 in vitro in intact mouse brain tissue and in the context of an animal behavioral paradigm of stress. Cdk5 only phosphorylates Thr-292, whereas ERK and Cdk1 phosphorylate both Thr-292 and Thr-286 MEK1. These sites interact in a kinase-specific manner and inhibit the ability of MEK1 to activate ERK. Thr-292 and Thr-286 MEK1 are phosphorylated in most mouse brain regions to stoichiometries of ~5% or less. Phosphorylation of Thr-292 MEK1 is regulated by cAMP-dependent signaling in mouse striatum in a manner consistent with negative feedback inhibition in response to ERK activation. Protein phosphatase 1 and 2A contribute to the maintenance of the basal phosphorylation state of both Thr-292 and Thr-286 MEK1 and that of ERK. Activation of the NMDA class of ionotropic glutamate receptors reduces inhibitory MEK1 phosphorylation, whereas forced swim, a paradigm of acute stress, attenuates Thr-292 MEK1 phosphorylation. Together, the data indicate that these inhibitory MEK1 sites phosphorylated by Cdk5 and ERK1 serve as mechanistic points of convergence for the regulation of ERK signaling by both slow and fast neurotransmission.

Indexed as

Amino Acid MotifsAnimalsBrainCDC2 Protein KinaseCyclin-Dependent Kinase 5MaleMAP Kinase Kinase 1MiceMice, Inbred C57BLMitogen-Activated Protein Kinase 3PhosphorylationCDC2 Protein KinaseCyclin-Dependent Kinase 5MAP Kinase Kinase 1Mitogen-Activated Protein Kinase 3Cdk5cyclin-dependent kinase (CDK)depressiondopamineERKMAPKMEK1NMDA receptor (NMDAR)phosphorylationstriatum

Identifiers

PMID25971971
PMCPMC4481230
OpenAlexW1513203770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.